XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues $ 9,317,473 $ 5,888,450 $ 25,107,391 $ 14,927,691
Cost of revenues 8,611,208 4,808,679 21,891,010 13,976,087
Research and development 2,630,632 6,315,613 12,534,775 20,719,989
Impairment of intangible assets 0 0 0 9,400,000
Selling, general, and administrative 4,936,486 5,147,166 16,100,696 24,971,438
Total operating costs and expenses 16,178,326 16,271,458 50,526,481 69,067,514
Operating loss (6,860,853) (10,383,008) (25,419,090) (54,139,823)
Other income (expense):        
Other income (expense), net 5,117 (410,233) 17,662 4,398,585
Interest expense (384,915) (552,983) (1,671,457) (1,651,222)
Nonoperating Income (Expense), Total (379,798) (963,216) (1,653,795) 2,747,363
Loss before provision for income taxes and noncontrolling interests (7,240,651) (11,346,224) (27,072,885) (51,392,460)
Provision (benefit) for income taxes 46,954 46,633 147,286 (3,610,097)
Net loss (7,287,605) (11,392,857) (27,220,171) (47,782,363)
Less - loss attributable to noncontrolling interests (405,072) (16,907) (522,005) (93,257)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (6,882,533) $ (11,375,950) $ (26,698,166) $ (47,689,106)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders $ (1.09) $ (2.06) $ (4.45) $ (10.40)
Weighted average common shares outstanding 6,323,427 5,523,912 6,001,572 4,586,757
Available for sale securities - net unrealized (loss) gain $ 0 $ (988) $ (486) $ (451)
Total other comprehensive loss 0 (988) (486) (451)
Comprehensive loss (7,287,605) (11,393,845) (27,220,657) (47,782,814)
Comprehensive loss attributable to noncontrolling interests (405,072) (16,908) (522,005) (93,257)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders $ (6,882,533) $ (11,376,937) $ (26,698,652) $ (47,689,557)